Showing results (51-60 of 604) with videos related to
Sort By:
Pageof 61
Pharmacoeconomics - Open|January 7, 2021
High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, et al.Pharmacoeconomics - Open|February 23, 2020
Cost Analysis of the Automated Examination of Urine with the Sysmex UN-Series™ in a Spanish PopulationÓscar Herráez Carrera, María Del Monte Jarabo BuenoPharmacoeconomics - Open|February 12, 2020
Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in FranceOlivier Heinzlef, Guillaume Molinier, Benoît van Hille, et al.Pharmacoeconomics - Open|April 18, 2023
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in FranceMegane Caillon, Benoit Brethon, Chrissy van Beurden-Tan, et al.Pharmacoeconomics - Open|April 19, 2023
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive AnalysisJulie Vanderpoel, Bruno Emond, Isabelle Ghelerter, et al.Pharmacoeconomics - Open|April 19, 2023
Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The NetherlandsRachel H P Schreurs, Arina J Ten Cate-Hoek, Hugo Ten Cate, et al.Pharmacoeconomics - Open|November 1, 2022
Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative MethodsR Brett McQueen, Nicholas D Mendola, Ivett Jakab, et al.Pharmacoeconomics - Open|September 28, 2022
Estimating the Incidence-Based Cost of Illness Due to Hematopoietic Stem Cell Transplantation Using One-Year Insurance Claim Data in KoreaSol Kwon, Hye-Young KangPharmacoeconomics - Open|September 19, 2022
"Don't Think Twice, It's All Right": Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in EnglandJiyeon Kang, John CairnsPharmacoeconomics - Open|November 23, 2023
Preferences for Living Arrangements in Dementia: A Discrete Choice ExperimentChristian Speckemeier, Carina Abels, Klemens Höfer, et al.Pageof 61